The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.

References

1. Centers for Disease Control and Prevention. RSV in Infants and Young Children. Available at: https://www.cdc.gov/rsv/high-risk/infants-young-children.html. Accessed March 2022.

2. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5):127-132. doi:10.1067/s0022-3476(03)00510-9

3. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus Seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018;67(2):71-76.

4. Arriola C, Kim L. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States 2014-15. J Pediatric Infect Dis Soc. 2020; 9587–595.

5. Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2):251-257. doi:10.1016/j.vaccine.2019.10.023

6. Centers for Disease Control and Prevention. The National Respiratory and Enteric Virus Surveillance System (NREVSS). RSV National Trends. Respiratory Syncytial Virus (RSV). . Available from: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html. Accessed March 2022.

7. Cohen R, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infectious Diseases Now. 2021; 51:418-423. https://doi.org/10.1016/j.idnow.2021.05.004

8. Centers for Disease Control and Prevention. Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States. Available from: https://emergency.cdc.gov/han/2021/han00443.asp. Accessed March 2022.

9. NSW Health. COVID-19 WEEKLY SURVEILLANCE IN NSW. Available from: https://www.health.nsw.gov.au/Infectious/covid-19/Documents/covid-19-surveillance-report-20220120.pdf. Accessed March 2022.

10. Public Health England. Weekly national Influenza and COVID-19 surveillance report Week 3 report (up to week 2 data). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048531/Weekly_Flu_and_COVID-19_report_w3.pdf. Accessed March 2022.

11. Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. JAMA Network. 2021;4(12):e2141779. doi:10.1001/jamanetworkopen.2021.41779.

12. Karron RA. Plotkin’s Vaccines. Seventh edition. Chapter 51, Respiratory Syncytial Virus Vaccines. Elsevier Inc. 2018.

13. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets. 2012;12(2):92-7.

14. Heylen E, Neyts J, Jochmans D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol. 2017;127:1-12.

15. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519-30.

16. Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants. Am J Perinatol. 2020;37(2):174-183. doi:10.1055/s-0039-1694008

17. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-1436. doi:10.1093/cid/cis211

18. Domachowske J, Halczyn J, Bonville C. Preventing Pediatric Respiratory Syncytial Virus Infection. Pediatr Ann. 2018;47(9). doi:10.3928/19382359-20180816-01

19. Viguria N, Martínez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L, Salcedo B, et al. (2018) Respiratory syncytial virus hospitalization in children in northern Spain. PLOS ONE. 13(11): e0206474. https://doi.org/10.1371/journal.pone.0206474

20. Ostransky, D., & Blais, F. X. (1991). Postviral bronchial hyperreactivity syndrome: recognizing asthma's great mimic. J American Osteopathic Association. 91(5), 465–475.

21. Fauroux B, Simões EAF, Checchia PA, et al. The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infect Dis Ther. 2017;6(2):173-197. doi:10.1007/s40121-017-0151-4

22. Wenzel, SE. Gibbs, RL, Lehr, MV, Simoes, EAF. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. American J Med. 2002; (112) 8: P627-633. DOI:https://doi.org/10.1016/S0002-9343(02)01095-1

23. Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): Transmission. Available from: https://www.cdc.gov/rsv/about/transmission.html. Accessed March 2022.

24. Assaker R, Colas A-E, Julien-Marsollier F, et al. Presenting Symptoms of COVID-19 in Children: A Meta-Analysis of Published Studies. Br J Anaesth. 2020;125(3):e330-e332. doi:10.1016/j.bja.2020.05.026external icon.